Translational Development Acquisition (TDAC) Other Accumulated Expenses (2024 - 2026)

Translational Development Acquisition (TDAC) has 3 years of Other Accumulated Expenses data on file, last reported at $136762.0 in Q1 2026.

• Quarterly Other Accumulated Expenses rose 509.92% year-over-year to $136762.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136762.0 (up 509.92% YoY) and the FY2025 annual result came in at $106762.0, up 5238.1% from the prior year.
• Other Accumulated Expenses rose to $136762.0 in Q1 2026, from $106762.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $136762.0 in Q1 2026 to a low of $2000.0 in Q4 2024.
• A 3-year average of $65245.2 and a median of $61762.0 in 2025 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses surged 5238.1% — and 2026, when it soared 509.92%.
• Tracing TDAC's Other Accumulated Expenses over 3 years: stood at $2000.0 in 2024, then surged by 5238.1% to $106762.0 in 2025, then rose by 28.1% to $136762.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $136762.0 (Q1 2026), $106762.0 (Q4 2025), and $76762.0 (Q3 2025), per Business Quant data.